Results for tag: "D1 Antagonist"

The D1 Antagonist market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. D1 Antagonists are a type of drug that block the action of dopamine, a neurotransmitter that plays a role in movement, cognition, and reward. These drugs are used to treat a variety of conditions, including schizophrenia, Parkinson's disease, and attention deficit hyperactivity disorder (ADHD). D1 Antagonists are also used to treat drug addiction, as they can reduce the rewarding effects of drugs such as cocaine and amphetamines. The D1 Antagonist market is highly competitive, with a number of companies offering products. Some of the major players in the market include AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more